© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Merck & Co., Inc. (MRK) stock surged +1.82%, trading at $121.93 on NYSE, up from the previous close of $119.75. The stock opened at $120.35, fluctuating between $120.35 and $122.66 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Feb 06, 2026 | 120.76 | 122.66 | 120.44 | 121.93 | 13.04M |
| Feb 05, 2026 | 118.31 | 122.43 | 118.31 | 119.75 | 24.01M |
| Feb 04, 2026 | 116.90 | 120.39 | 116.50 | 118.33 | 21.94M |
| Feb 03, 2026 | 111.67 | 118.46 | 111.44 | 115.84 | 25.79M |
| Feb 02, 2026 | 110.12 | 113.89 | 109.95 | 113.37 | 17.99M |
| Jan 30, 2026 | 108.59 | 110.54 | 107.95 | 110.27 | 19.03M |
| Jan 29, 2026 | 107.33 | 109.93 | 107.10 | 108.34 | 13.54M |
| Jan 28, 2026 | 106.85 | 107.93 | 106.03 | 106.90 | 7.46M |
| Jan 27, 2026 | 107.50 | 108.35 | 106.84 | 107.92 | 7.91M |
| Jan 26, 2026 | 107.80 | 108.42 | 107.06 | 107.40 | 9.74M |
| Jan 23, 2026 | 109.09 | 109.09 | 107.21 | 108.18 | 10.31M |
| Jan 22, 2026 | 110.78 | 111.32 | 108.59 | 109.18 | 9.34M |
| Jan 21, 2026 | 109.19 | 111.97 | 108.73 | 111.11 | 12.81M |
| Jan 20, 2026 | 108.11 | 109.64 | 106.93 | 109.45 | 15.24M |
| Jan 16, 2026 | 110.72 | 110.73 | 108.43 | 108.83 | 14.71M |
| Jan 15, 2026 | 110.62 | 111.58 | 108.45 | 110.97 | 11.77M |
| Jan 14, 2026 | 108.97 | 111.23 | 107.95 | 111.01 | 11.93M |
| Jan 13, 2026 | 109.05 | 109.31 | 107.22 | 108.26 | 9.34M |
| Jan 12, 2026 | 110.97 | 111.46 | 108.78 | 109.19 | 10.56M |
| Jan 09, 2026 | 110.87 | 112.48 | 110.22 | 110.53 | 10.9M |
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
| Employees | 73000 |
| Beta | 0.3 |
| Sales or Revenue | $59.87B |
| 5Y Sales Change% | 0.413% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |